12 Mar 2015
(MENAFN) Jordan’s Hikma Pharmaceuticals Plc registered USD1.49 billion revenue for the full year of 2014, marking a 9 percent increase. However, the firm forecasts a 6 percent revenue growth 2015, Reuters reported.
The Jordanian company said that 2015 revenue would be impacted by around USD45 million, or by 3 percent, that is if current exchange rates continued unchanged.
The firm’s pretax profit increased USD362 million in 2014, marking an increase from the USD298 million of 2013 due to a stronger-than-expected performance in the injectable drugs business.
“Earnings upgrades have been a key driver of outperformance over last 24 months, but a sub-par 2H14 performance coupled with a soft 2015 guidance will now break that cycle in our view,” Citi analysts said.
04 Aug 2025
HM the King’s Support for Youth is an Inspirational Model for Their Empowerment Journey
28 Jul 2025
BBK discloses its financial results for the half year ended 30th June 2025
20 Jul 2025
CBB approves the transfer of the retail banking operations of HSBC Bank Middle East, Bahrain Branch to BBK
08 Jul 2025
BBK proudly launches the third edition of “Grow” and welcomes 20 Bahraini graduates
03 Jul 2025
BBK hosts executive leadership session on digital assets in collaboration with Rain
02 Jul 2025
BBK launches the largest-ever Al Hayrat Prizes, offering BD 5 million to over 2,000 winners
16 Jun 2025
BBK and CrediMax Offer Exclusive 20% Discount on Turkish Airlines Flights for Cardholders
25 May 2025
BBK strengthens commitment to sports development through strategic partnership with Bahrain Basketball Association
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more